Navigation Links
Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
Date:10/2/2007

ity when compared to reagents produced through traditional methods.

The SEQer catalog of antibodies addresses a number of well-known challenges associated with currently available reagents. Specifically, deficiencies in the ability to replicate the three dimensional conformation of target proteins through synthetic immunogens have resulted in reagents that do not reliably recognize or differentiate their intended targets. This, in turn, limits reagent performance and creates a level of uncertainty regarding the data produced with traditionally produced reagents. The SEQer antibody is focused on addressing the loss of productivity in research and development endeavors.

"The performance of our SEQer antibodies has been demonstrated with our many private and public collaborators in numerous assays," Mr. Knight said. "The programs have included significantly large screens for oncology markers and the ability to stain disease-associated proteins across thousands of clinical biopsy samples. More targeted studies have shown the ability to differentiate highly conserved proteins in cell sorting assays, the ability to react with traditionally elusive proteins of interest, and be directed through SDI's design algorithms to target functional sites in monoclonal applications."

SDI's GAT-produced antibodies are significantly better than traditional protein/peptide-produced antibodies, as they are produced in vivo by the host animal's natural immune system, and are therefore able to behave both chemically and mechanically as any naturally produced antibody would.

Oncology Focus

The SEQer oncology-focused portfolio is comprised of antibody tools that target proteins associated with cancer pathogenesis and progression, thereby succeeding in delivering usable data for more proteins and in more applications. SDI strategically focused on the area of oncology, as more than half of NIH-funded research and the majority of proteomic efforts are currently focu
'/>"/>

SOURCE Strategic Diagnostics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
2. New Advances in Gastric Diagnostics: Smaller is Better
3. West Nile Virus Screening and Diagnostics Technology Emerges In Step with North American Outbreak
4. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
5. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
6. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
7. Immunomedics Reports Initial Clinical Results With Hpam4 For Pancreatic Cancer Therapy
8. Pharmacopeia Announces Positive Results from Initial DARA Clinical Trial
9. Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO
10. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
11. Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  Galderma  ... Award" from the Journal of Drugs in Dermatology ... Clinical Conference (ODAC). The event is January 17-20, 2014, at the ... . The ODAC is a ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
(Date:1/15/2014)... Tegra Medical is very pleased to announce the appointment of ... Executive Officer.  Mark was promoted from his current role of ... four facilities in Massachusetts , ... Medical in 2012 with 20+ years of broad-based operations, sales, ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3
... Shire plc (LSE: SHP, Nasdaq: SHPGY ), ... its long-term extension to its open label Phase I/II study ... therapy for patients with type 1 Gaucher disease.  The data ... Gaucher Disease (EWGGD) in Cologne, Germany , and add ...
... July 1 Sagent Pharmaceuticals, Inc., a privately ... Food and Drug Administration (FDA) has approved the Company,s ... a vital anticoagulant, preventing the formation of clots and ... in surgical and dialysis settings.  According to IMS, 2009 ...
Cached Medicine Technology:Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 2Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 3Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 4Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 5Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV(R) (Velaglucerase Alfa) Through 69 Months 6FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 2FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 3FDA Approves Sagent Pharmaceuticals' Heparin Sodium Injection, USP 4
(Date:4/18/2014)... The Gerontologist reports that among older ... decrease in anxiety about death and increases in life ... In particular, listening to gospel music is associated with ... in sense of control. , These associations are similar ... of both low- and high-socioeconomic status. , The article, ...
(Date:4/18/2014)... April 18, 2014) Benaroya Research Institute at Virginia ... blocking a particular molecule in metastatic breast cancer reduces ... of lung metastases. BRI scientists have found in models ... tumors by 60 - 80 percent and can keep ... The $1.8 million five-year grant comes from the National ...
(Date:4/18/2014)... Northwestern Medicine scientists could lead to potential new treatments ... with scleroderma. , Fibrosis, or scarring, is a ... skin and lungs can lead to serious organ damage ... new therapeutic options centers on findings made by Swati ... the role that a specific protein plays in promoting ...
(Date:4/17/2014)... new pain relief targets that could be used ... at King,s College London made the discovery when ... periphery of the body. , Dr Marzia Malcangio ... underlying pain generation and our findings could help ... , One potential side effect of some chemotherapy ...
(Date:4/17/2014)... School of Medicine report that older women, plucky individuals ... are more likely to be compassionate toward strangers than ... this month,s issue of the International Journal of ... with better health and well-being as we age, the ... outcomes of individuals whose deficits in compassion put them ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Benaroya Research Institute evaluates immunology approach to blocking breast cancer 2Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2
... The July issue of the health journal Epidemiology has published ... of cancer are higher if there is associated infertility. ... Rockville, Maryland, and her team followed 12,193 U.S. women ... risk among infertile women with that of the general population. ...
... and Drug Administration (FDA) issued a public health advisory to ... marketing of Tysabri (nataluzimab) the drug meant to treat relapsing ... FDA in 2004. , ,FDA supports the decision ... the use of the product in clinical trials. However, it ...
... passive smoking when in the womb of the mother, may ... the study had conducted an 11-year observation of incidence of ... smoking is significantly related to incidence of asthma in childhood. ... contribute towards the incidence of asthma in children. ,Researchers ...
... bypass surgery that is often done as a measure for ... // heart disease. ,One of the most common ... that reduces the size of the stomach and allows the ... with psychological and behavioral support, this procedure has become one ...
... Pharmaceuticals Inc (RPI), they have stated that have ... largest chain store in the US, for outstanding performance ... a global company with more than 1.3 million associates ... 10 countries. , ,RPI is based in Jacksonville, ...
... Scientists have made a new discovery regarding the cells ... , ,Researchers from Wake Forest University School of ... area of the brain can slow the release of ... seizures. Researchers have found that treatment of epilepsy that ...
Cached Medicine News:
... a sterile, nonpyrogenic, viscoelastic preparation of ... weight fraction of sodium hyaluronate., ,Healon ... dissolved in physiological sodium chloride phosphate ... weight polymer is made up of ...
... System is designed to give two viscoelastic ... be used differently and sequentially to perform ... choice of the viscoelastic is based upon ... each to facilitate performance of the surgical ...
... During fiscal year 2004, Biomet ... Navigation System to the global market, ... procedures. The Acumen technology was developed ... private company based in Hollywood, Florida. ...
... in awhile, a product comes along that ... in its category. The new StealthStation TREON ... a product. Built on the phenomenal success ... surgical navigation system in the worldthe new ...
Medicine Products: